© 2022 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
November 10, 2021
Immune checkpoint inhibitors an induce resistance through activation of additional immune checkpoints such as LAG-3. Research around LAG3 will be important for the future.
October 18, 2021
Although osimertinib has been shown to overcome T790M-mediated mutations in the second-line setting, as with other EGFR tyrosine kinase inhibiors progression on osimertinib is inevitable.
May 22, 2021
During a virtual Targeted Oncology Case-Based Roundtable event, Timothy F. Burns, MD, PHD, discussed the treatment of non–small cell lung cancer based on clinical trial research.